← Back to Search
Tumour Radiosensitivity Is Associated With Immune Activation In Solid Tumours.
T. Strom, L. Harrison, A. Giuliano, M. Schell, S. Eschrich, Anders E. Berglund, W. Fulp, R. Thapa, D. Coppola, Sungjune Kim, J. Frakes, J. Foekens, J. Mulé, J. Torres-Roca
Published 2017 · Biology, Medicine
Download PDFAnalyze on Scholarcy
PURPOSE Our goal was to determine whether tumour radiosensitivity is associated with activation of the immune system across all tumour types as measured by two gene expression signatures (GESs). METHODS We identified 10,240 genomically profiled distinct solid primary tumours with gene expression analysis available from an institutional de-identified database. Two separate GESs were included in the analysis, the radiosensitivity index (RSI) GES (a 10-gene GES as a measure of radiosensitivity) and the 12-chemokine (12-CK) signature (a 12-gene GES as a measure of immune activation). We tested whether the RSI and 12-CK were associated with each other across all tumour samples and, in an exploratory analysis, their prognostic significance in predicting distant metastasis-free survival (DMFS) among a well-characterised, independent cohort of 282 early-stage breast cancer cases treated with surgery and post-operative radiation alone without systemic therapy. The lower the RSI score, the higher the tumour radiosensitivity; whereas, the higher the 12-CK score the higher the immune activation. RESULTS Using an RSI cut-point of ≤0.3745, RSI-low tumours (n = 4,291, 41.9%) had a significantly higher median 12-CK GES value (0.54 [-0.136, 1.095]) compared with RSI-high tumours (-0.17 [-0.82, 0.42]; p < 0.001) across all tumour samples, indicating that radiosensitivity is associated with immune activation. In an exploratory analysis of early-stage breast cancer cases, a multivariable model with patient age, RSI and 12-CK provided a strong composite model for DMFS (p = 0.02), with RSI (hazard ratio [HR] 0.63 [95% confidence interval 0.36, 1.09]) and 12-CK (HR 0.66 [0.41, 1.04]) each providing comparable contributions. CONCLUSIONS Tumour radiosensitivity is associated with immune activation as measured by the two GESs.
This paper references
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
J. Weber (2015)
Exploration, normalization, and summaries of high density oligonucleotide array probe level data.
R. Irizarry (2003)
Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes
C. T. Garnett (2004)
Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta‐analysis
C. Ragin (2007)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
A. Ribas (2015)
Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer.
T. Strom (2015)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A. Postow (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
R. Motzer (2015)
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant.
K. Reynders (2015)
Nivolumab in previously untreated melanoma without BRAF mutation.
C. Robert (2015)
Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection.
K. Ahmed (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
Current clinical trials testing combinations of immunotherapy and radiation.
M. Crittenden (2015)
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Xiangjiao Meng (2015)
The radiosensitivity index predicts for overall survival in glioblastoma
K. Ahmed (2015)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated.
S. Demaria (2004)
12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
J. Messina (2012)
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts
Y. Pawitan (2005)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
J. Larkin (2015)
Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions.
M. B. Bernstein (2014)
Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.
J. Torres-Roca (2015)
Implementing personalized medicine in a cancer center.
D. Fenstermacher (2011)
Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response
M. Mihm (2015)
The abscopal effect associated with a systemic anti-melanoma immune response.
Emily F. Stamell (2013)
Immunologic correlates of the abscopal effect in a patient with melanoma.
M. Postow (2012)
Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4+ FoxP3+ regulatory T cells
F. Wirsdörfer (2014)
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias
B. Bolstad (2003)
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
A. Sharabi (2014)
Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response.
C. Tang (2015)
Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform.
S. Eschrich (2009)
Seminars in Radiation Oncology. Introduction.
S. Formenti (2015)
Prediction of radiation sensitivity using a gene expression classifier.
J. Torres-Roca (2005)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
H. Barker (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
A. Eggermont (2015)
Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling.
D. Coppola (2011)
A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation.
S. Eschrich (2009)
Validation of a Radiosensitivity Molecular Signature in Breast Cancer
S. Eschrich (2012)
Iterative rank-order normalization of gene expression microarray data
E. A. Welsh (2012)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
E. Reits (2006)
Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
A. Gupta (2012)
The effects of therapeutic irradiation on lymphocytes and immunity
S. Order (1977)
Human papillomavirus and survival of patients with oropharyngeal cancer.
K. Ang (2010)
Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium.
D. Hallahan (1996)
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
C. Robert (2015)
Prognostic and predictive markers for the new immunotherapies.
K. Mahoney (2014)
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
S. Ansell (2015)
Subtypes of breast cancer show preferential site of relapse.
M. Smid (2008)
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Y. Wang (2005)
Combination cancer immunotherapy and new immunomodulatory targets
K. Mahoney (2015)
Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer
Christina Twyman-Saint Victor (2015)
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.
S. Dovedi (2014)
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody
M. Z. Dewan (2009)
Radiation enhances regulatory T cell representation.
Evelyn L. Kachikwu (2011)
Summaries of Affymetrix GeneChip probe level data.
R. Irizarry (2003)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.
A. Sharabi (2015)
This paper is referenced by
Turning foes to friends: targeting cancer-associated fibroblasts
Xueman Chen (2018)
Radiosensitivity Differences between EGFR Mutant and Wild-Type Lung Cancer Cells are Larger at Lower Doses
Mai Anakura (2019)
Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC.
X. S. Sun (2018)
The Future of Radiation Oncology in Soft Tissue Sarcoma
A. Naghavi (2018)
Exploring the role of survivin in neuroendocrine neoplasms
A. Hanif (2020)
Integrating Mathematical Modeling into the Roadmap for Personalized Adaptive Radiation Therapy.
H. Enderling (2019)
Cancer-associated Fibroblasts: Origins, Heterogeneity and Functions in Tumor Microenvironment
K. Dzobo (2020)
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
A. Vilgelm (2019)
Harnessing tumor immune ecosystem dynamics to personalize radiotherapy
G. Daniel Grass (2020)
Hadron Therapy Based on Laser Acceleration in the Plasma Channel Using Oxygen Ionization
Vala Mehryar Alviri (2019)
Personalizing Radiation Treatment Delivery in the Management of Breast Cancer
K. Ahmed (2018)
Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors
M. Sjöström (2018)
Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management
K. Ahmed (2019)
Endogenous Retrovirus Activation as a Key Mechanism of Anti-Tumor Immune Response in Radiotherapy
A. Lee (2020)
Clinical update on head and neck cancer: molecular biology and ongoing challenges
E. Alsahafi (2019)
Genomic stratification based on radiosensitivity and PD-L1 for tailoring therapeutic strategies in cervical cancer.
Xintong Lyu (2019)
Outils pour la prédiction de la réponse tumorale et des tissus sains en oncologie radiothérapie
O. Riou (2019)
Tertiary lymphoid structures in the era of cancer immunotherapy
C. Sautès-Fridman (2019)
Cytokine Modulation in Breast Cancer Patients Undergoing Radiotherapy: A Revision of the Most Recent Studies
Raffaella Marconi (2019)